Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Pyr-AI

From Wikipedia, the free encyclopedia

Pyr-AI
Clinical data
Other names2-PYI; 2-Pyrrolidinylindane; 1-(2-Indanyl)pyrrolidine; Compound 10j
Drug classStimulant
ATC code
  • None
Identifiers
  • 1-(2,3-dihydro-1H-inden-2-yl)pyrrolidine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H17N
Molar mass187.286 g·mol−1
3D model (JSmol)
  • C1CCN(C1)C2CC3=CC=CC=C3C2
  • InChI=1S/C13H17N/c1-2-6-12-10-13(9-11(12)5-1)14-7-3-4-8-14/h1-2,5-6,13H,3-4,7-10H2
  • Key:PAOQQDSGNKTTRU-UHFFFAOYSA-N

Pyr-AI, also known as 2-pyrrolidinylindane (2-PYI), is a stimulant drug of the 2-aminoindane family.[1] It is the analogue of 2-aminoindane (2-AI) in which the amine has been replaced with a pyrrolidine group.[1] The drug has been described as having strong and long-lasting amphetamine-like effects in rodents.[1][2] Other 2-aminoindanes like 2-AI itself and NM-2-AI are known to act as potent monoamine releasing agents and reuptake inhibitors.[3][4] Pyr-AI was first described in the scientific literature by 1973.[1][2]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Brandt SD, Braithwaite RA, Evans-Brown M, Kicman AT (2013). "Aminoindane Analogues". Novel Psychoactive Substances. Elsevier. pp. 261–283. doi:10.1016/b978-0-12-415816-0.00011-0. ISBN 978-0-12-415816-0. Retrieved 2 November 2025. A 'strong amphetamine-type activity' has been reported for the pyrrolidine derivative of 2-AI (26, Fig. 11.10) [41] and 'a long duration' of activity was observed at the 10mg/kg dose in mice. Details about the procedure were not provided but neuropharmacological screenings were based on observational methods [48]. A piperidine derivative (27, PIP-AI), on the other hand, showed analgesic properties comparable to meperidine [41].
  2. 1 2 Solomons E, Sam J (December 1973). "2-Aminoindans of pharmacological interest". Journal of Medicinal Chemistry. 16 (12): 1330–1333. doi:10.1021/jm00270a004. PMID 4765859.
  3. Luethi D, Liechti ME (April 2020). "Designer drugs: mechanism of action and adverse effects". Archives of Toxicology. 94 (4): 1085–1133. Bibcode:2020ArTox..94.1085L. doi:10.1007/s00204-020-02693-7. PMC 7225206. PMID 32249347.
  4. Halberstadt AL, Brandt SD, Walther D, Baumann MH (March 2019). "2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors". Psychopharmacology. 236 (3): 989–999. doi:10.1007/s00213-019-05207-1. PMC 6848746. PMID 30904940.
[edit]